These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 38459598)

  • 1. Detection of HER2 expression using
    Zhao L; Xing Y; Liu C; Ma S; Huang W; Cheng Z; Zhao J
    Breast Cancer Res; 2024 Mar; 26(1):40. PubMed ID: 38459598
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular imaging of HER2 expression in breast cancer patients using a novel peptide-based tracer
    Shi J; Du S; Wang R; Gao H; Luo Q; Hou G; Zhou Y; Zhu Z; Wang F
    J Transl Med; 2023 Jan; 21(1):19. PubMed ID: 36631812
    [TBL] [Abstract][Full Text] [Related]  

  • 3. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intra-individual comparison of
    Bénard F; Harsini S; Wilson D; Zukotynski K; Abikhzer G; Turcotte E; Cossette M; Metser U; Romsa J; Martin M; Mar C; Saad F; Soucy JP; Eigl BJ; Black P; Krauze A; Burrell S; Nichol A; Tardif JC
    Lancet Oncol; 2022 Dec; 23(12):1499-1507. PubMed ID: 36343655
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic activity in bone metastases of breast and prostate cancer were similar as studied by
    Pietrzak A; Czepczynski R; Wierzchoslawska E; Cholewinski W
    Hell J Nucl Med; 2017; 20(3):237-240. PubMed ID: 29177262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the diagnostic and prognostic values of 99mTc-MDP-planar bone scintigraphy, 131I-SPECT/CT and 18F-FDG-PET/CT for the detection of bone metastases from differentiated thyroid cancer.
    Qiu ZL; Xue YL; Song HJ; Luo QY
    Nucl Med Commun; 2012 Dec; 33(12):1232-42. PubMed ID: 23111353
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective evaluation of planar bone scintigraphy, SPECT, SPECT/CT, 18F-NaF PET/CT and whole body 1.5T MRI, including DWI, for the detection of bone metastases in high risk breast and prostate cancer patients: SKELETA clinical trial.
    Jambor I; Kuisma A; Ramadan S; Huovinen R; Sandell M; Kajander S; Kemppainen J; Kauppila E; Auren J; Merisaari H; Saunavaara J; Noponen T; Minn H; Aronen HJ; Seppänen M
    Acta Oncol; 2016; 55(1):59-67. PubMed ID: 25833330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined
    Wu J; Zhang X; Jia Z; Zhou X; Qi R; Ji H; Sun J; Sun C; Teng Z; Lu G; Chen X
    Mol Pharm; 2022 Sep; 19(9):3405-3411. PubMed ID: 35972444
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of [
    Chen Z; Fu F; Li F; Zhu Z; Yang Y; Chen X; Jia B; Zheng S; Huang C; Miao W
    Mol Imaging Biol; 2018 Oct; 20(5):846-856. PubMed ID: 29497956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of an Affibody-based Molecular Probe and
    Guo X; Zhou N; Liu J; Ding J; Liu T; Song G; Zhu H; Yang Z
    Radiology; 2024 Jun; 311(3):e232209. PubMed ID: 38888484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a
    Zhao L; Liu C; Xing Y; He J; O'Doherty J; Huang W; Zhao J
    Mol Pharm; 2021 Sep; 18(9):3616-3622. PubMed ID: 34328338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [
    Zheng S; Chen Z; Huang C; Chen Y; Miao W
    Ann Nucl Med; 2019 Feb; 33(2):135-143. PubMed ID: 30392070
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Noninferiority of
    Dai D; Rollo FD; Bryant J; Kim EE
    Contrast Media Mol Imaging; 2018; 2018():8969714. PubMed ID: 29736155
    [No Abstract]   [Full Text] [Related]  

  • 14. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
    Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
    Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective comparison of whole-body bone SPECT and sodium 18F-fluoride PET in the detection of bone metastases from breast cancer.
    Abikhzer G; Srour S; Fried G; Drumea K; Kozlener E; Frenkel A; Israel O; Fogelman I; Kagna O
    Nucl Med Commun; 2016 Nov; 37(11):1160-8. PubMed ID: 27536906
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II Trial Assessing the Repeatability and Tumor Uptake of [
    Gondry O; Caveliers V; Xavier C; Raes L; Vanhoeij M; Verfaillie G; Fontaine C; Glorieus K; De Grève J; Joris S; Luyten I; Zwaenepoel K; Vandenbroucke F; Waelput W; Thyparambil S; Vaneycken I; Cousaert J; Bourgeois S; Devoogdt N; Goethals L; Everaert H; De Geeter F; Lahoutte T; Keyaerts M
    J Nucl Med; 2024 Feb; 65(2):178-184. PubMed ID: 38302159
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential utility of [
    Li Y; Deng L; Feng Y; Liu L; Lv F; Qiu L
    Eur Radiol; 2023 Dec; 33(12):9378-9389. PubMed ID: 37454338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of 99mtechnetium-pertechnetate and 123iodide SPECT with FDG-PET in patients suspicious for breast cancer.
    Buchmann I; Riedmüller K; Hoffner S; Mack U; Aulmann S; Haberkorn U
    Cancer Biother Radiopharm; 2007 Dec; 22(6):779-89. PubMed ID: 18158769
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative
    Coskun N; Cagdas B; Yildirim N
    Hell J Nucl Med; 2022; 25(2):132-137. PubMed ID: 35913859
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is (99m)Tc-MDP whole body bone scintigraphy adjuvant to (18)F-FDG-PET for the detection of skeletal metastases?
    Sahin E; Zincirkeser S; Akcan AB; Elboga U
    J BUON; 2014; 19(1):291-6. PubMed ID: 24659678
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.